No Data
No Data
Pfizer's Bondholders Cheer News of Activist Investor Starboard's $1 Billion Investment
RSV vaccine sales in the US dropped significantly, as the 'most imaginative product' faced a heavy blow from the CDC.
①Independent pharmacists reported that the demand for RSV vaccines in the autumn has decreased by two-thirds compared to a year ago; ②In September last year, an average of approximately 0.44 million people received glaxosmithkline or pfizer's RSV vaccines per week; whereas this September, the average number of people per week is around 0.157 million.
Pfizer CEO's Job Is at Risk. A Shot of Discipline Could Help. -- WSJ
Daily short sale tracking: NVIDIA's short volume increased by 7 million, with a short sale ratio of 8%
NVIDIA(NVDA.US) ranked top of the list had the largest change in short volume (7.95 million shares), and the short volume ratio of Royal Bank of Canada(RY.US) reached 66.32%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
GSK Arexvy Protects From RSV Over Three Full Seasons
glaxosmithkline (GSK.US) claims that the protective effect of the RSV vaccine can last for three quarters.
GlaxoSmithKline (GSK.US) said on Tuesday that its respiratory syncytial virus (RSV) vaccine has protective effects in the three quarters after vaccination.